ODI Pharma demonstrates clear operational progress and improved commercial outlook
ODI Pharma AB ("ODI Pharma" or the "Company") provides an operational update following recent improvements in its commercial performance. Strategic and practical measures implemented in recent quarters have begun to show clear results, supported by a more stable regulatory environment and smoother product flows into the Polish market.
ODI Pharma's commercial activity has strengthened in recent months as earlier operational and strategic measures begin to take effect. The Company now benefits from a more stable supply situation, more predictable import and export processes, and an efficient route to pharmacies and patients through its long-standing distribution partners. These partners continue to provide broad and reliable market access, reinforcing ODI's position in the Polish medical cannabis market.
The improved conditions in cross-border product movement, together with completed product approvals and steady operational readiness, have created a more predictable commercial environment. The positive developments seen this year are the result of both external improvements in the regulatory and logistical landscape and ODI's focused efforts to adapt to and capitalise on these changes.
This progress marks a significant improvement from earlier expectations and gives the Company a more robust and internally supported outlook for reaching healthy and stable profitability. ODI is now better equipped to meet demand, maintain product availability, and operate with greater consistency. This strengthened operational position is expected to support reliable order intake and contribute to a solid and sustainable financial position for ODI Pharma.
For more information on ODI Pharma, please contact:
Volker Wiederrich, Chairman, ODI Pharma AB
E-mail: info@odipharma.com
ODI Pharma AB
ODI Pharma, based on its European network, subsidiaries and affiliates, is a producer and representative of finished pharmaceutical cannabis products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. The Company will continue to team up with the most knowledgeable and best renown partners in the industry to achieve its goals.